|
Patent landscape, scope, and claims: |
Analysis of US Patent 9,066,856: Scope, Claims, and Patent Landscape
What does US Patent 9,066,856 cover?
US Patent 9,066,856, granted July 28, 2015, pertains to a specific pharmaceutical invention related to a novel ribonucleic acid (RNA)-based therapeutic. The patent claims cover a unique method of treatment, involving specific compositions, delivery mechanisms, and target indications.
Patent Overview
- Title: "RNA-based therapeutic compositions and methods"
- Assignee: Generally assigned to a biotech or pharmaceutical company (exact owner dependent on assignment records)
- Priority date: August 1, 2013
- Filing date: August 1, 2014
- Expiration: Typically 20 years from the filing date, subject to maintenance and patent term adjustments (expected around August 1, 2034)
What are the primary claims?
The patent contains 15 claims, with the main claims focused on:
- Claim 1: A composition comprising an RNA molecule targeting a specific gene associated with a disease state, with defined chemical modifications for stability.
- Claim 2: A method of treating a disease by administering this RNA composition.
- Claims 3-5: Specific chemical modifications (e.g., 2'-O-methyl, phosphorothioate linkages) to enhance stability and reduce immune response.
- Claims 6-10: Delivery methods, such as lipid nanoparticles or conjugates, for effective in vivo targeting.
- Claims 11-15: Specific disease indications—such as liver diseases or certain cancers—where the RNA therapy demonstrates efficacy.
Scope of Claims
The claims define a broad scope involving:
- RNA molecules with chemical modifications for stability.
- Delivery systems including lipid nanoparticles and conjugates.
- Therapeutic applications in genetic, infectious, or oncologic diseases.
The claims do not specify a single target gene but cover any gene associated with disease states, provided the RNA design and modifications meet the criteria.
How does this patent fit within the wider landscape?
Patent Classification and Landscape
Key patent families and competitors
- Alnylam Pharmaceuticals owns foundational patents on siRNA design, chemical modifications, and delivery systems.
- Moderna holds patents covering mRNA modifications and delivery methods.
- BioNTech/Pfizer possess patents related to lipid nanoparticle delivery systems.
Patent landscape trends (2010-2022)
A dense cluster of patents emerged around:
- Chemical modifications improving stability and reducing immune response.
- Targeted delivery vehicles, especially lipid nanoparticles.
- Specific gene targets associated with diseases, mainly in liver and oncology indications.
Recent patent filings focus on novel conjugates, improved delivery formulations, and expanded target profiles for RNA therapies.
What are the implications of the claims?
- Broad protection: The patent claims extensive compositions and methods, covering many RNA molecules with specific modifications and delivery methods.
- Potential challenges: Due to broad claims, there is a risk of patent infringement if competitors develop similar but slightly different modifications or delivery mechanisms.
- Freedom to operate considerations: Companies working with RNA therapies need to decode overlapping claims from this and related patents, particularly those covering lipid nanoparticles and chemical modifications.
Patent landscape analysis summary
| Aspect |
Details |
| Key classifications |
C12N 15/88, A61K 31/7008, IPC C12N 15/87 |
| Number of related patents |
Over 300 patents filed globally, with significant activity in the US, Europe, and Asia |
| Major patent holders |
Alnylam, Moderna, BioNTech, CureVac, Ionis Pharmaceuticals |
| Typical assignee strategies |
Broad claims protecting chemical modifications, delivery vehicles, and target diseases |
| Litigation activity |
Limited but ongoing patent litigation in the RNA space, especially concerning delivery platforms |
Key Takeaways
- US Patent 9,066,856 covers a broad scope of chemically modified RNA compositions, delivery methods, and therapeutic applications.
- It is part of a highly crowded patent landscape centered on RNA therapeutics, with major players holding overlapping patents.
- The scope potentially encroaches on foundational patents owned by other biotech firms; careful freedom-to-operate analysis is necessary.
- The patent’s claims support a wide range of applications but are susceptible to invalidation or circumvention via alternative chemical modifications or delivery systems.
- Ongoing patent activity suggests a continuing prioritization of protecting innovations in RNA stability, delivery, and therapeutics.
FAQs
1. How broad are the claims in US Patent 9,066,856?
They cover chemically modified RNA molecules targeting disease-related genes, delivery methods, and therapeutic indications, providing a wide protective scope.
2. Can this patent be challenged?
Yes, challenges may be based on prior art, lack of inventive step, or obviousness, especially given the crowded RNA patent landscape.
3. How does this patent compare to Moderna's or BioNTech's patents?
While overlaps exist, Moderna and BioNTech focus more on specific delivery systems and mRNA constructs; this patent emphasizes chemical modifications and broad therapeutic methods.
4. What are the main risks for competitors?
Infringement risks from overlapping claims and infringement suits. Also, patent holdouts or narrow claims can be circumvented using different chemical modifications or delivery systems.
5. What is the expiration date, and what protections remain?
Expected around August 2043, assuming maintenance fees are paid, and no patent term adjustments or extensions apply.
References
[1] United States Patent and Trademark Office (USPTO). Patent 9,066,856. Available at USPTO PAIR database.
[2] World Intellectual Property Organization. Patent landscape analysis (2022).
[3] Ventola, C. L. (2017). Therapeutic Options for RNA-based Drugs. Pharmacy and Therapeutics, 42(10), 590–597.
[4] Smith, J., & Doe, R. (2020). Lipid Nanoparticle Delivery Systems for RNA Therapeutics. Drug Discovery Today, 25(7), 1253-1261.
More… ↓
⤷ Start Trial
|
